Skip to main
BMEA

BMEA Stock Forecast & Price Target

BMEA Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Biomea Fusion is positioned to disrupt the metabolic disease market with its promising drug pipeline and has strong potential for growth and success.

Bears say

Biomea Fusion is a clinical stage diabetes and obesity medicines company with promising drug candidates in development, however, there is limited data to fully support the efficacy of their lead candidate, icovamenib. Additionally, with over 60 approved therapies for diabetes and none addressing the central driver of disease progression, the market potential for Biomea's drugs may be overstated. Furthermore, the company's early stage drug, BMF-650, has yet to show significant weight loss results and its tolerability is still a concern. Overall, the limited data and potential competition in the market make Biomea Fusion's stock a risky investment at this time.

BMEA has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biomea Fusion Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biomea Fusion Inc (BMEA) Forecast

Analysts have given BMEA a Strong Buy based on their latest research and market trends.

According to 5 analysts, BMEA has a Strong Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biomea Fusion Inc (BMEA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.